NO20042142L - Farmasoytisk sammensetning som omfatter en adenosin A1/A2-agonist og en natriumhydrogenutvekslingsinhibitor - Google Patents

Farmasoytisk sammensetning som omfatter en adenosin A1/A2-agonist og en natriumhydrogenutvekslingsinhibitor

Info

Publication number
NO20042142L
NO20042142L NO20042142A NO20042142A NO20042142L NO 20042142 L NO20042142 L NO 20042142L NO 20042142 A NO20042142 A NO 20042142A NO 20042142 A NO20042142 A NO 20042142A NO 20042142 L NO20042142 L NO 20042142L
Authority
NO
Norway
Prior art keywords
adenosine
agonist
pharmaceutical composition
sodium hydrogen
hydrogen exchange
Prior art date
Application number
NO20042142A
Other languages
English (en)
Norwegian (no)
Inventor
James M Downey
Xu Zhelong
Umesh Shukla
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203596A external-priority patent/GB0203596D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20042142L publication Critical patent/NO20042142L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20042142A 2001-11-02 2004-05-25 Farmasoytisk sammensetning som omfatter en adenosin A1/A2-agonist og en natriumhydrogenutvekslingsinhibitor NO20042142L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33631501P 2001-11-02 2001-11-02
GB0203596A GB0203596D0 (en) 2002-02-15 2002-02-15 Pharmaceutical composition comprising of adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor
PCT/US2002/035096 WO2003039528A1 (en) 2001-11-02 2002-11-01 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor

Publications (1)

Publication Number Publication Date
NO20042142L true NO20042142L (no) 2004-05-25

Family

ID=26246972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042142A NO20042142L (no) 2001-11-02 2004-05-25 Farmasoytisk sammensetning som omfatter en adenosin A1/A2-agonist og en natriumhydrogenutvekslingsinhibitor

Country Status (16)

Country Link
US (1) US20040248928A1 (es)
EP (1) EP1443916A1 (es)
JP (1) JP2005511590A (es)
KR (1) KR20050042225A (es)
CN (1) CN1585634A (es)
BR (1) BR0213820A (es)
CA (1) CA2465364A1 (es)
HR (1) HRP20040385A2 (es)
HU (1) HUP0401853A2 (es)
IL (1) IL161676A0 (es)
MA (1) MA27073A1 (es)
MX (1) MXPA04003124A (es)
NO (1) NO20042142L (es)
PL (1) PL369074A1 (es)
RU (1) RU2004116686A (es)
WO (1) WO2003039528A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP4664797B2 (ja) * 2005-10-13 2011-04-06 ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー Mri装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1056729T1 (en) * 1998-02-27 2005-04-30 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl)guanidine derivatives for the treatment of ischemia
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia

Also Published As

Publication number Publication date
IL161676A0 (en) 2004-09-27
PL369074A1 (en) 2005-04-18
EP1443916A1 (en) 2004-08-11
KR20050042225A (ko) 2005-05-06
MA27073A1 (fr) 2004-12-20
JP2005511590A (ja) 2005-04-28
CA2465364A1 (en) 2003-05-15
US20040248928A1 (en) 2004-12-09
HRP20040385A2 (en) 2005-06-30
RU2004116686A (ru) 2005-03-27
MXPA04003124A (es) 2004-11-29
WO2003039528A1 (en) 2003-05-15
BR0213820A (pt) 2004-08-31
HUP0401853A2 (hu) 2004-12-28
CN1585634A (zh) 2005-02-23

Similar Documents

Publication Publication Date Title
NO20033565D0 (no) Acylerte indanylaminer og deres anvendelse som farmasöytiske midler
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
DK1401806T3 (da) Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
DE60203994D1 (de) Matrixsteckverbinder
IS7111A (is) Lyfjablanda sem felur í sér róteindadæluhemil og sýrubindandi efni
NO20044095L (no) 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
NO20034324D0 (no) Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
DK1375503T3 (da) Dioxinoderivater og deres anvendelse som dopaminagonister
DE60211076D1 (de) Datenübertragung zwischen virtuellen Adressen
NO20052512D0 (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
DK1470242T3 (da) Enzymatiske kredsprocesanalyser for homocystein og cystathionin
NO20032830L (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celleproliferasjonsinhibitorer
NO20030929L (no) Guanidinobenzamider som MC4-R agonister
NO20042906L (no) Deutererte, substituerte pyrazolybenzylsulfonamider og medikamenter som inneholder disse forbindelsene
NO20040254L (no) Farmasoytiske sammensetninger som inneholder terbinafin og anvendelse derav
IS7065A (is) Áætlun um lyfjaskammta við meðferð og lyfjasamsetningar til getnaðarvarna í neyð
NO20042907L (no) Deutererte, substituerte dihydrofuranoner og medikamenter som inneholder disse forbindelsene
NO20005758D0 (no) Farmasöytisk preparat som inneholder levotyroksin-natrium
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20041432L (no) Sammensetninger som innbefatter COX-2 inhibitorer og aspirin.
AU2002356284A8 (en) Fast path message transfer agent
NO995513D0 (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister
NO20035300D0 (no) Aminokinolin- og aminopyridinderivater og deres anvendelse som adenosin A<N>3-ligander
NO20042142L (no) Farmasoytisk sammensetning som omfatter en adenosin A1/A2-agonist og en natriumhydrogenutvekslingsinhibitor
ATE439847T1 (de) Ribavirin syrup formulierungen